The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates

Critical Care Medicine

Volumn 28, Issue 7, 2000, Pages 2584-2590

  Cheung, Po Yin ^a   Sawicki, Grzegorz ^a   Salas, Eduardo ^b   Etches, Phil C ^a   Schulz, Richard ^a   Radomski, Marek W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Unit of Research and Development   (Spain)

Author keywords

Aggregation; Extracorporeal membrane oxygenation; Gelatinases; Matrix metalloproteinases; Neonate; Nitric oxide; Oxidative stress; Platelet; Selectins; Tissue inhibitors of metalloproteinases

Indexed keywords

COLLAGEN; GELATINASE A; GELATINASE B; NITRATE; NITRIC OXIDE; NITRITE; PADGEM PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CRITICAL ILLNESS; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRACORPOREAL OXYGENATION; HUMAN; NEWBORN; NEWBORN INTENSIVE CARE; OXIDATIVE STRESS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0033852546     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200007000-00067     Document Type: Article

References (36)

1. 1. Hooper NM: Families of zinc metalloproteinases. FEBS Lett 1994; 354:1-6
2. 2. Spinale FG, Coker ML, Thomas CV, et al: Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure -Relation to ventricular and myocyte function. Circ Res 1998 82:482-495
3. 3. Sawicki G, Salas E, Murat J, et al: Release of gelatinase A during platelet activation mediates aggregation. Nature 1997; 386:616-619
4. 4. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ: Matrix metalloproteinase inhibitors. Invest New Drugs 1997; 15:61-75
5. 5. Stetler-Stevenson WG, Krutzsch HC, Liotta LA: Tissue inhibitor of metalloproteinase (TIMP-2): A new member of the metalloproteinase inhibitor family. J Biol Chem 1989; 264:17374-17379
6. 6. Ichiba S, Bartlett RH: Current status of extracorporeal membrane oxygenation for severe respiratory failure. Artif Organs 1996; 20:120-123
7. 7. Neonatal ECMO Registry of the Extracorporeal Life Support Organization (ELSO). Ann Arbor, MI, ELSO, January 1998
8. 8. Gemmell CH, Ramirez SM, Yeo EL, et al: Platelet activation in whole blood by artificial surfaces: Identification of platelet-derived microparticles and activated platelet binding to leukocytes as material-induced activation events. J Lab Clin Med 1995; 125:276-287
9. 9. Salas E, Miszta-Lane H, Radomski MW: Regulation of platelet function by nitric oxide and other nitrogen-and oxygen-derived reactive species. In: Handbook of Experimental Pharmacology: Platelets and Their Factors. Vol 26. Von Bruchhausen F, Walter U (Eds). New York, Springer-Verlag, 1997, pp 371-397
10. 10. Robinson TM, Kickler TS, Walker LK, et al: Effect of extracorporeal membrane oxygenation on platelets in newborns. Crit Care Med 1993; 21:1029-1034
11. 11. Bick RL: Alterations of hemostasis associated with cardiopulmonary bypass: Pathophysiology, prevention, diagnosis, and management. Semin Thromb Hemost 1976; 3:59-82
12. 12. Finer NN, Tierney A, Ainsworth W: Venovenous extracorporeal membrane oxygenation: The effects of proximal internal jugular cannulation. J Pediatr Surg 1996; 31: 1391-1395
13. 13. Cheung P-Y, Salas E, Etches PC, et al: Inhaled nitric oxide and inhibition of platelet aggregation. Lancet 1998; 351:1181-1182
14. 14. Heussen C, Dowdle EB: Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980; 102:196-202
15. 15. Sawicki G, Matsuzaki A, Janowska-Wieczorek A: Expression of the active form of MMP-2 on the surface of the leukemic cells accounts for their in vitro invasion. J Cancer Res Clin Oncol 1998; 124:245-252
16. 16. Powers JC, Harper JW: Inhibitors of metalloproteinases. In: Proteinase Inhibitors. Barrett AJ, Salvesen G (Eds). Amsterdam, Elsevier, 1986, pp 219-300
17. 17. Laemmli UK: Cleavage of structural proteins during the assembly of the head bacteriophage T4. Nature 1970; 227:680-685
18. 18. Green LC, Wagner DA, Glogowski J, et al: Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982; 126: 131-138
19. 19. Bevilacqua MP: Identification of an inducible endothelial leucocyte adhesion molecule. Proc Natl Acad Sci U S A 1987; 84: 9238-9242
20. 20. Newman W: Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J Immunol 1993; 150:644-654
21. 21. Yamada H, Hirose Y, Toyoshima M, et al: Activation of endothelium in cardiac surgery: The circulating levels of soluble E-selectin as a marker of the activation of endothelium. Masui 1997; 46:478-483
22. 22. Baylin C, Vallance P: Measurement of nitrite and nitrate levels in plasma and urine - What does this measure tell us about the activity of the endogenous nitric oxide system? Curr Opin Nephrol Hypertens 1998; 7:59-62
23. 23. Tedder TF, Steeber DA, Chen A, et al: The selectins: Vascular adhesion molecules. FASEB J 1985; 9:866-873
24. 24. Fijnheer R, Frijns CJ, Korteweg J, et al: The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997; 77: 1081-1085
25. 25. Sawicki G, Sanders EJ, Salas E, et al: Localization and translocation of MMP-2 during aggregation of human platelets. Thromb Haemost 1998; 80:836-839
26. 26. Rinder HM, Snyder EL: Activation of platelet concentrate during preparation and storage. Blood Cells 1992; 18:445-456
27. 27. Graves DF, Chernin JM, Kurusz M, et al: Anticoagulation practices during neonatal extracorporeal membrane oxygenation: Survey results. Perfusion 1996; 11:461-466
28. 28. King DJ, Kelton JG: Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100:535-540
29. 29. Anderson HL III, Edmunds LH Jr: Coagulation, anticoagulation and the interaction of blood and artificial surfaces. In: ECMO: Extracorporeal Life Support in Critical Care. Zwischenberger JB, Bartlett RH (Eds). Ann Arbor, MI, ELSO, 1995, pp 53-72
30. 30. Kitano Y, Takata M, Miyasaka K, et al: Evaluation of an extracorporeal membrane oxygenation system using a non-porous membrane oxygenator and a new method for heparin coating. J Pediatr Surg 1997; 32: 691-697
31. 31. Cottrell ED, Kappa JR, Stenach N, et al: Temporary inhibition of platelet function with iloprost (ZK36374) preserves canine platelets during extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg 1988; 96: 535-541
32. 32. Mellgren K, Friberg LG, Mellgren G, et al: Nitric oxide in the oxygenator sweep gas reduces platelet activation during experimental perfusion. Ann Thorac Surg 1996; 61: 1194-1198
33. 33. Annich GM, Meinhardt JP, Mowery KA, et al: Reduced platelet activation and thrombosis in extracorporeal circuits coated with nitric oxide release polymers. Crit Care Med 2000; 28:915-920
34. 34. Parsons SL, Watson SA, Steele RJ: Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 1997; 23:526-531
35. 35. Nagaya M, Futamura M, Kato J, et al: Application of a new anticoagulant (Nafamostat mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation - A preliminary report. J Pediatr Sury 1997; 32:531-535
36. 36. Radomski A, Sawicki G, Olson DM, et al: The role of nitric oxide and metalloproteinases in the pathogenesis of hyperoxia-induced lung injury in newborn rats. Br J Pharmacol 1998; 125:1455-1462